Telmisartan to prevent recurrent stroke - the PRoFESS study: was the baby thrown out with the bathwater? by McInnes, G.T.
 
 
 
 
 
 
 
McInnes, G.T. (2009) Telmisartan to prevent recurrent stroke - the 
PRoFESS study: was the baby thrown out with the bathwater? Stroke, 40 
(5). pp. 1938-1940. ISSN 0039-2499 
 
http://eprints.gla.ac.uk/18227/ 
 
Deposited on: 18 January 2012 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Emerging Therapies
Section Editors: Marc Fisher, MD, and Kennedy Lees, MD
Telmisartan to Prevent Recurrent Stroke: The
PRoFESS Study
Was the Baby Thrown Out With the Bathwater?
Gordon T. McInnes, BSc, MD, FRCP
In retrospect, the choice of PRoFESS as the acronym forthis trial may be considered unwise. The dictionary defi-
nition of the verb “to profess” is “to declare or to claim, often
insincerely or falsely.” What does PRoFESS declare and can
we believe the claim?
Blood pressure reduction initiated several months after
stroke reduces cardiovascular complications, including recur-
rent stroke.1 Would earlier intervention be beneficial? To
address this question, the Prevention Regimen for Effectively
Avoiding Second Strokes (PRoFESS) trial evaluated the
effects of therapy with the angiotensin receptor blocker, telm-
isartan. Blockade of the renin–angiotensin system is said to
reduce the risk of stroke independent of blood pressure.2,3
Indeed, a small study of unusual design4 suggested that an
angiotensin receptor blocker started soon after stroke reduced
rates of death and cardiovascular events despite no blood
pressure reduction.
Telmisartan at 80 mg daily was compared with placebo in
20 392 patients with prior ischemic stroke. Because PRo-
FESS used a factorial design allowing comparison of 2
antiplatelet regimens, patients with hemorrhagic stroke were
excluded. All patients received treatment for blood pressure
control at the discretion of the investigators. The primary
outcome was recurrent stroke. Secondary outcomes were major
cardiovascular events and the incidence of new-onset diabetes.
The median interval to randomization was 15 days post-
stroke and median follow-up was 2.5 years. Although 74% of
participants had a history of hypertension, mean blood
pressure at randomization was 144.1/83.8 mm Hg. During
follow-up, blood pressure fell in both groups but more so in
the telmisartan arm (mean blood pressure difference
3.8/2.0 mm Hg).
The results strongly support the null hypothesis. Hazard
ratios were 0.95 (95% CI, 0.86 to 1.04; P0.23) for recurrent
stroke, 0.94 (0.87 to 1.01; P0.11) for major cardiovascular
events, and 0.82 (0.65 to 1.04; P0.10) for new-onset
diabetes. The findings were consistent across various sub-
groups of stroke and in prespecified subgroups of patients.
There were no interactions with the antiplatelet regimens.
Thus, therapy with telmisartan initiated soon after ische-
mic stroke and continued for 2.5 years did not significantly
lower the rate of recurrent stroke, major cardiovascular
events, or new diabetes.
Critique
The landmark PROGRESS trial1 demonstrated reduced risk
of recurrent stroke and other cardiovascular events with blood
pressure-lowering started at least 2 weeks after stroke, al-
though the median time to randomization was 8 months. In
contrast, PRoFESS failed to provide evidence of benefit when
treatment was started after a median period of 15 days. Time
to randomization was 10 days or less in 40% of participants
and this subgroup showed similar results as those in the entire
group. However, approximately 50% of the PRoFESS popu-
lation was randomized beyond 2 weeks, as in PROGRESS,1
but experienced no benefit from blood pressure reduction.
What Is the Explanation for the Outcome
Differences Between PRoFESS
and PROGRESS?
In PRoFESS, but not in PROGRESS, patients with hemor-
rhagic strokes were excluded and baseline blood pressure was
lower (144/84 mm Hg versus 147/86 mm Hg). Although
patients with intracerebral hemorrhages and highish blood
pressure might be expected to show proportionally greater
benefits from blood pressure reduction, the PROGRESS
findings1 suggest that neither of these characteristics influ-
enced outcome, at least in the long-term. The PRoFESS
authors suggest that lesser blood pressure-lowering is a
possible explanation. They note that most of the benefit in
PROGRESS1 was seen in the group receiving perindopril
plus indapamide in which blood pressure reduction was
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12.3/5.0 mm Hg, whereas those receiving perindopril alone
experienced a blood pressure reduction of only 4.9/
2.8 mm Hg and no significant benefit.
Can We Disentangle Blood Pressure
Reduction From Mode of Action?
This explanation is unconvincing if there is indeed a blood
pressure-independent beneficial effect of blocking the renin–
angiotensin system as speculated by the PRoFESS authors. In
favor of this hypothesis is superficial interpretation of the
results of the HOPE2 and LIFE5 trials, whereas the findings of
PRoFESS and the monotherapy arm of PROGRESS1 are
more difficult to reconcile. Of course, it may be that stroke
prevention in HOPE2 was in fact due to the blood pressure-
lowering effect of the angiotensin converting enzyme inhib-
itor; blood pressure changes may well have been underesti-
mated in that study.6 In LIFE,5 the advantage of losartan over
atenolol in stroke prevention may have been due to the
shortcoming of the -blocker7 rather than any speculated
advantage of the angiotensin receptor blocker.
In PRoFESS, blood pressure was lower in the telmisartan
group throughout. Differences were maximal in the first
month and declined over time. This pattern is typical of trials
in which one group is randomized initially to placebo.8
Compared with the telmisartan group, more patients random-
ized to placebo received additional antihypertensive therapy,
minimizing by an estimated 33% the difference in blood
pressure between the groups. However, the disadvantaged
placebo group did not catch up. Because events are usually
evenly spaced over a trial, the variability in differential blood
pressure control over time means that reliance on average
blood pressure difference underestimates the influence of
early blood pressure changes. Furthermore, at the end of
PRoFESS, only approximately 70% of patients randomized to
telmisartan remained on an angiotensin receptor blocker,
whereas 2.5% of those randomized to placebo were receiving
an angiotensin receptor blocker, diluting the influence of
angiotensin receptor blockade. Thus, the study design was not
optimal for teasing out the potentially competing influences
of blood pressure reduction and mode of action.
Was PRoFESS Powered Adequately?
There is concern that the study was underpowered. The
protocol specified a sample size of 15 500 patients, which
would yield 2170 with recurrent stroke during 4 years’
follow-up. Despite an increase in sample size to over 20 000,
only 1814 participants had recurrent strokes in 2.5 years of
follow-up. It is a frequent finding that event rate in outcome
trials is less than that predicted. Perhaps, the PRoFESS
investigators now regret the decision to modify the power
calculation during the study.
What About Intermediate Outcomes?
Not only did telmisartan-based therapy fail to reduce the risk
of recurrent stroke and cardiovascular events, but the inci-
dence of new-onset diabetes was not influenced significantly.
Furthermore, atrial fibrillation was significantly more com-
mon after telmisartan. These observations are in sharp con-
trast with findings from other trials with angiotensin
converting enzyme inhibitors and angiotensin receptor
blockers in which protection against new diabetes and
atrial fibrillation has been suggested.9,10 Thus, PRoFESS
calls into question these intermediate end points as mark-
ers for benefits beyond blood pressure-lowering of drugs
that block the renin–angiotensin system.
What Can Be Salvaged From the Wreckage
of PRoFESS?
Post hoc explanatory analyses suggest the possibility of
time-dependent benefit with telmisartan. No significant ben-
efit was seen up to 6 months after randomization, although a
small but significant advantage for stroke and cardiovascular
events was seen thereafter. The differences between the 2
periods was significant and adjustment for postrandomization
blood pressure did not markedly affect the estimates. Although
these analyses must be seen as hypothesis-generating, there is
some support from other trials. In PROGRESS,1 HOPE,2 and
LIFE,5 little benefit was apparent in the first 6 months with
graded and continuing lessening of rates of stroke and major
cardiovascular events thereafter. These findings are also
consistent with those from TRANSCEND11 (telmisartan ver-
sus placebo in high-risk patients intolerant of angiotensin
converting enzyme inhibitors) and other trials of antihyper-
tensive agents12 and lipid-lowering therapy.13,14 Considerable
time may be necessary to modify the atherosclerotic process.
The mean duration of therapy in PRoFESS may have been
too short at 2.5 years; assuming constant hazard, average time
to event was only 1.25 years. In PROGRESS,1 mean duration
of therapy was 4 years and in HOPE2 4.5 years.
In trials of new interventions to prevent further cardiovas-
cular events when added to existing therapies, only moderate
(10% to 15%) benefits can be realistically expected. To
ensure that full benefit is apparent, treatment periods have to
be prolonged. This is perhaps the most important message
from PRoFESS. The pressure to design and conduct major
trials to generate results as quickly as possible must be
resisted. Otherwise, the huge investment, both financial and
in patients, may be wasted. After more than 50 000 patient-
years devoted to PRoFESS, we simply cannot declare
whether early reduction of blood pressure after stroke has
long-term benefits and we certainly can make no reliable
claim to support any advantage or disadvantage of renin–an-
giotensin system blockade. Expediency may have resulted in
the baby being thrown out with the bathwater.
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